Systemic Lupus Erythematosus: Definition, Pathogenesis And Treatment

dc.creatorPostal M.
dc.creatorAppenzeller S.
dc.date2011
dc.date2015-06-30T20:31:30Z
dc.date2015-11-26T14:50:47Z
dc.date2015-06-30T20:31:30Z
dc.date2015-11-26T14:50:47Z
dc.date.accessioned2018-03-28T22:02:07Z
dc.date.available2018-03-28T22:02:07Z
dc.identifier9781617615528
dc.identifierAutoimmune Disorders: Symptoms, Diagnosis And Treatment. Nova Science Publishers, Inc., v. , n. , p. 167 - 190, 2011.
dc.identifier
dc.identifier
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84892022654&partnerID=40&md5=bf4298d252e53381d103435cfc0e2563
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/108228
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/108228
dc.identifier2-s2.0-84892022654
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1254263
dc.descriptionSystemic lupus erythematosus (SLE) is a multisystemic disease characterized by profound alterations of the immune system that contribute to inflammation and tissue damage. The diverse presentations of SLE range from rash and arthritis through anemia and thrombocytopenia to serositis, nephritis, seizures, and psychosis. SLE should be part of the differential diagnosis in virtually any patient presenting with one of these clinical problems, especially in female patients between 15 and 50 years of age. Since 90% of patients with SLE are female, an important role for sex hormones seems likely, but a protective role for male hormones is also possible. Pathogenic auto-antibodies are the primary cause of tissue damage in patients with SLE. The production of these antibodies arises by means of complex mechanisms involving every key facet of the immune system. There are no diagnostic criteria, only classification criteria. In order to consider SLE for research practice, the patient must present at least four of 11 criteria established by the American College of Rheumatology (ACR). Many different elements of the system are potential targets for therapeutic drugs in SLE. The treatment involves immunosuppressive medications like high-dose of corticosteroids, azathioprine, and cyclophosphamide. Mycophenolate mofetil and rituximab have been used in association with corticosteroids (oral or intravenous pulse therapy) in SLE patients. Besides, anti-malarial medications are used not only to control disease, but also to improve survival and to reduce the risk of thrombosis. The aim of this review is to describe symptoms of SLE that may vary from rash and arthritis through seizures, and psychosis. We will also include a review on current treatment and new medications. © 2011 Nova Science Publishers, Inc. All rights reserved.
dc.description
dc.description
dc.description167
dc.description190
dc.descriptionGrossman, J.M., Kenneth, C.K., Definition
dc.descriptionclassification
dc.descriptionactivity and damage indices (2002), In: Dubois' Lupus Erythematosus
dc.description6th ed. Lippincott
dc.descriptionWilliams & Wilkins: Philadelphia
dc.descriptionPARahman, A., Isenberg, D.A., Systemic lupus erythematosus (2008) N Engl J Med., 358, pp. 929-939
dc.descriptionPons-Estel, G.J., Alarcón, G.S., Scofield, L., Understanding the epidemiology and progression of systemic lupus erythematosus (2010) Semin Arthritis Rheum., 39, p. 25768
dc.descriptionHuemer, C., Huemer, M., Dorner, T., Incidence of pediatric rheumatic diseases in a regional population in Austria (2001) J Rheumatol., 28, pp. 2116-2119
dc.descriptionHuang, J.L., Yao, T.C., See, L.C., Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: a nation-wide prospective population-based study in Taiwan (2004) Clin Exp Rheumatol., 22, pp. 776-780
dc.descriptionBae, S.C., Fraser, P., Liang, M.H., The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the "prevalence gradient hypothesis" (1998) Arthritis Rheum., 41, pp. 2091-2099
dc.descriptionMcCarty, D.J., Manzi, S., Medsger Jr., T.A., Incidence of systemic lupus erythematosus. Race and gender differences (1995) Arthritis Rheum., 38, pp. 1260-1270
dc.descriptionJohnson, A.E., Gordon, C., Palmer, R.G., Bacon, P.A., The prevalence and incidence of systemic lupus erythematosus in Birmingham
dc.descriptionEngland. Relationship to ethnicity and country of birth (1995) Arthritis Rheum., 38, pp. 551-558
dc.descriptionHopkinson, N.D., Doherty, M., Powell, R.J., The prevalence and incidence of systemic lupus erythematosus in Nottingham
dc.descriptionUK
dc.description1989-1990 (1993) Br J Rheumatol., 32, pp. 110-115
dc.descriptionChakravarty, E.F., Bush, T.M., Manzi, S., Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000, estimates obtained using hospitalization data (2007) Arthritis Rheum., 56, pp. 2092-2094
dc.descriptionSamanta, A., Feehally, J., Roy, S., High prevalence of systemic disease and mortality in Asian subjects with systemic lupus erythematosus (1991) Ann Rheum Dis., 50, pp. 490-492
dc.descriptionHochberg, M.C., The incidence of systemic lupus erythematosus in Baltimore
dc.descriptionMaryland
dc.description1970-1977 (1985) Arthritis Rheum., 28, pp. 80-86
dc.descriptionBossingham, D., Systemic lupus erythematosus in the far north of Queensland (2003) Lupus., 12, pp. 327-331
dc.descriptionSegasothy, M., Phillips, P.A., Systemic lupus erythematosus in Aborigines and Caucasians in central Australia: a comparative study (2001) Lupus., 10, pp. 439-444
dc.descriptionBoyer, G.S., Templin, D.W., Lanier, A.P., Rheumatic diseases in Alaskan Indians of the southeast coast: high prevalence of rheumatoid arthritis and systemic lupus erythematosus (1991) J Rheumatol., 18, pp. 1477-1484
dc.descriptionPeschken, C.A., Esdaile, J.M., Systemic lupus erythematosus in North American Indians: a population based study (2000) J Rheumatol., 27, pp. 1884-1891
dc.descriptionHochberg, M.C., Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (1997) Arthritis Rheum., 40, p. 1725
dc.descriptionPetri, M., Review of classification criteria for systemic lupus erythematosus (2005) Rheum Dis Clin North Am., 31, pp. 245-254
dc.descriptionTench, C.M., McCurdie, I., White, P.D., D'Cruz, D.P., The prevalence and associations of fatigue in systemic lupus erythematosus (2000) Rheumatology., 39, pp. 1249-1254. , (Oxford)
dc.descriptionManson, J.J., Rahman, A., Systemic lupus erythematosus (2006) Orphanet J Rare Dis., 1, p. 6
dc.descriptionWeening, J.J., D'Agati, V.D., Schwartz, M.M., The classification of glomerulonephritis in systemic lupus erythematosus revisited (2004) J Am Soc Nephrol., 15, pp. 241-250
dc.descriptionWest;, S.G., Neuropsychiatry lupus (1994) Rheum Dis Clin North Am., 20, pp. 129-158
dc.descriptionHanly;, J.G., Walsh, N.M., Sangalang;, V., Brain pathology in systemic lupus erythematosus (1992) J Rheumatol., 19, pp. 732-741
dc.descriptionJohnson, R.T., Richardson, E.P., The neurological manifestations of systemic lupus erythematosus (1968) Medicine., 47, pp. 337-369. , (Baltimore)
dc.descriptionThe American College of Rheumatology nomenclature and case definitions for neuropsychiatry lupus syndromes (1999) Arthritis Rheum., 42, pp. 599-608
dc.descriptionPanopalis, P., Julian, L., Yazdany, J., Impact of memory impairment on employment status in persons with systemic lupus erythematosus (2007) Arthritis Rheum., 57, pp. 1453-1460
dc.descriptionSultan, S.M., Begum, S., Isenberg, D.A., Prevalence
dc.descriptionpatterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems (2003) Rheumatology., 42, pp. 230-234. , (Oxford)
dc.descriptionRopes, M.W., (1976) Systemic lupus erythematosus., , Cambridge
dc.descriptionMA: Harvard University Press
dc.descriptionFries, J.F., Holamn, H., Systemic lupus erythematosus: a clinica analysis (1975) Philadelphia: WB Saunders
dc.descriptionUramoto, K.M., Michet, C.J., Thumboo, J., Trends in the incidence and mortality of systemic lupus erythematosus
dc.description1950-1992 (1999) Arthritis Rheum., 42, pp. 46-50
dc.descriptionParan, D., Fireman, E., Elkayam, O., Pulmonary disease in systemic lupus erythematosus and the antiphospholpid syndrome (2004) Autoimmun Rev., 3, pp. 70-75
dc.descriptionYeh, T.T., Yang, Y.H., Lin, Y.T., Lu, C.S., Chiang, B.L., Cardiopulmonary involvement in pediatric systemic lupus erythematosus: a twenty-year retrospective analysis (2007) J Microbiol Immunol Infect., 40, pp. 525-531
dc.descriptionSzekanecz, Z., Shoenfeld, Y., Lupus and cardiovascular disease: the facts (2006) Lupus., S15, pp. 3-10
dc.descriptionJacobsen, S., Petersen, J., Ullman, S., A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinic factors of prognostic value (1998) Clin Rheumatol., 17, pp. 478-484
dc.descriptionLaw, W.G., Thong, B.Y., Lian, T.Y., Kong, K.O., Chng, H.H., Acute lupus myocarditis: clinical features and outcome of an oriental case series (2005) Lupus., 14, pp. 827-831
dc.descriptionTincani, A., Rebaioli, C.B., Taglietti, M., Shoenfeld, Y., Heart involvement in systemic lupus erythematosus
dc.descriptionanti-phospholipid syndrome and neonatal lupus (2006) Rheumatology., 45 (SUPPL. 4), pp. 48-13
dc.descriptionGalli, M., Luciani, D., Bertolini, G., Barbui, T., Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature (2003) Blood., 101, pp. 1827-1832
dc.descriptionSomers, E., Magder, L.S., Petri, M., Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus (2002) J Rheumatol., 29, pp. 2531-2536
dc.descriptionSultan, S.M., Ioannou, Y., Isenberg, D.A., A review of gastrointestinal manifestations of systemic lupus erythematosus (1999) Rheumatology., 38, pp. 917-932. , (Oxford)
dc.descriptionCervera, R., Khamashta, M.A., Font, J., Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1, 000 patients (2003) Medicine., 82, pp. 299-308. , (Baltimore)
dc.descriptionFauci, A.S., Haynes, B., Katz, P., The spectrum of vasculitis: clinical
dc.descriptionpathologic
dc.descriptionimmunologic and therapeutic considerations (1978) Ann Intern Med., 89, pp. 660-676
dc.descriptionRuiz-Irastorza, G., Lima, F., Alves, J., Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies (1996) Br J Rheumatol., 35, pp. 133-138
dc.descriptionRuiz-Irastorza, G., Khamashta, M., Hughes, G.R.V., Systemic lupus erythematosus and antiphospholipid syndrome during pregnancy: maternal and fetal complications and their management (2000) MAJ., 2, pp. 462-469
dc.descriptionRahman, P., Gladman, D.D., Urowitz, M.B., Clinical predictors of fetal outcome in systemic lupus erythematosus (1998) J Rheumatol., 25, pp. 1526-1530
dc.descriptionWelsch, S., Branch, D.W., Antiphospholipid syndrome in pregnancy: obstetric concerns and treatment (1997) Rheum Dis Clin North Am., 23, pp. 71-84
dc.descriptionMeng, C., Lockshin, M., Pregnancy in lupus (1999) Curr Opin Rheumatol., 11, pp. 348-351
dc.descriptionJulkunen, H., Kaaja, R., Siren, M.K., Immune-mediated congenital heart block (CHB): identifying and counseling patients at risk for having children with CHB (1998) Semin Arthritis Rheum., 28, pp. 97-106
dc.descriptionWong, K.L., Chan, F.Y., Lee, C.P., Outcome of pregnancy in patients with systemic lupus erythematosus. A prospective study (1991) Arch Intern Med., 151, pp. 269-273
dc.descriptionBermas, B.L., Hill, J.A., Effects of immunosuppressive drugs during pregnancy (1995) Arthritis Rheum., 38, pp. 1722-1732
dc.descriptionWallace, D.J., Antimalarial agents and lupus (1994) Rheum Dis Clin North Am., 20, p. 24363
dc.descriptionWalport, M.J., Black, C.M., Batchelor, J.R., The immunogenetics of SLE (1982) Clin Rheum Dis., 8, pp. 3-21
dc.descriptionSontheimer, R.D., Photoimmunology of lupus erythematosus and dermatomyositis: a speculative review (1996) Photochem Photobiol., 42, pp. 583-594
dc.descriptionJames, J.A., Kaufman, K.M., Farris, A.D., An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus (1997) J Clin Invest., 100, pp. 3019-3026
dc.descriptionLevine, J.S., Koh, J.S., The role of apoptosis in autoimmunity: immunogen
dc.descriptionantigen and accelerant (1999) Semin Nephrology., 19, pp. 34-47
dc.descriptionHuck, S., Deveaud, E., Namane, A., Abnormal DNA methylation and deoxycytosine content in nucleosomes from lymphocytes undergoing apoptosis (1999) FASEB. J, 3, pp. 1415-1422
dc.descriptionAndrade, F., Cascioloa-Rosen, L., Rosen, A., Apoptosis in systemic lupus erythematosus. Clinical implications Rheum Dis Clin North Am., 26, pp. 215-227. , 200
dc.descriptionHerrmann, M., Voll, R.E., Zoller, O.M., Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus (1998) Arthritis Rheum., 41, pp. 1241-1250
dc.descriptionMason, L.J., Isenberg, D., The pathogenesis of systemic lupus erythematosus (2005), pp. 809-829. , In: Oxford textbook of clinical nephrology
dc.description3rd ed Oxford
dc.descriptionEngland: Oxford University Press;Bynoe, M.S., Grimaldi, C.M., Diamond, B., Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells (2000) Proc Natl Acad Sci. USA, 97, pp. 2703-2708
dc.descriptionChang, D.M., Lan, J.L., Lin, H.Y., Luo, S.F., Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized
dc.descriptiondouble-blind
dc.descriptionplacebo-controlled trial (2002) Arthritis Rheum., 46, pp. 2924-2927
dc.descriptionChrousos, G.P., The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation (1995) N Engl J Med., 332, pp. 1351-1362
dc.descriptionChan, O.T., Madaio, M.P., Sholmchik, M.J., The central and multiple roles of B cells in lupus pathogenesis (1999) Immunol Rev., 169, pp. 107-121
dc.descriptionHolbrow, E.J., Weir, D.M., Jhonson, G.D., A serum factor in lupus erythematosus with affinity for tissue nuclei (1957) Br Med J., 2, pp. 732-734
dc.descriptionKoffler, D., Schur, P.H., Kunkel, H.G., Immunological studies concerning the nephritis of systemic lupus erythematosus (1967) J Exp Med., 126, pp. 607-624
dc.descriptionIsenberg, D.A., Shoenfeld, Y., Walport, M., Detection of cross-reactive anti-DNA antibody idiotypes in the serum of systemic lupus erythematosus patients and of their relatives (1985) Arthritis Rheum., 28, pp. 999-1007
dc.descriptionNg, K.P., Manson, J.J., Rahman, A., Isenberg, D.A., Associations of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus (2006) Arthritis Rheum., 55, pp. 900-904
dc.descriptionMannik, M., Merrill, C.E., Stamps, L.D., Wener, M.H., Multiple autoantibodies form the glomerular immune deposits in patients with systemic lupus erythematosus (2003) J Rheumatol., 30, pp. 1495-1504
dc.descriptionBuyon, J.P., Clancy, R.M., Maternal autoantibodies and congenital heart block: mediators
dc.descriptionmarkers
dc.descriptionand therapeutic approach (2003) Semin Arthritis Rheum., 33, pp. 140-154
dc.descriptionClancy, R.M., Kapur, R.P., Molad, Y., Immunohistologic evidence supports apoptosis
dc.descriptionIgG deposition
dc.descriptionand novel macrophage/fibroblast crosstalk in the pathologic cascade leading to congenital heart block (2004) Arthritis Rheum., 50, pp. 173-182
dc.descriptionKowal, C., Degiorgio, L.A., Lee, J.Y., Human lupus autoantibodies against NMDA receptors mediate cognitive impairment (2006) Proc Natl Acad Sci U S A, 103, pp. 19854-19859
dc.descriptionElkon, K.B., Parnassa, A.P., Foster, C.R., Lupus autoantibodies target ribosomal P proteins (1985) J Exp Med., 162, pp. 459-471
dc.descriptionBriani, C., Lucchetta, M., Ghirardello, A., Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study (2009) J Autoimmun., 32, p. 7984
dc.descriptionAbdel-Nasser, A.M., Ghaleb, R.M., Mahmoud, J.A., Association of anti-ribosomal P protein antibodies with neuropsychiatry and other manifestations of systemic lupus erythematosus (2008) Clin Rheumatol., 27, pp. 1377-1385
dc.descriptionHirohata, S., Arinuma, Y., Takayama, M., Association of cerebrospinal fluid anti-ribosomal p protein antibodies with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus (2007) Arthritis Res Ther., 9, pp. R44
dc.descriptionTzioufas, A.G., Tzortzakis, N.G., Panou-Pomonis, E., The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease (2000) Ann Rheum Dis., 59, pp. 99-104
dc.descriptionChindalore, V., Neas, B., Reichlin, M., The association between anti-ribosomal P antibodies and active nephritis in systemic lupus erythematosus (1998) Clin Immunol Immunopathol., 87, pp. 292-296
dc.descriptionHulsey, M., Goldstein, R., Scully, L., Antiribosomal P protein antibodies in systemic lupus erythematosus: a case-control study correlating hepatic and renal disease (1995) Clin Immunol Immunopathol., 74, pp. 252-256
dc.descriptionMonova, D., Argirova, T., Monov, S., Anti-ribosomal P antibodies in patients with lupus glomerulonephritis (2001) Clin Nephrol., 55, pp. 425-426
dc.descriptionArnett, F.C., Reichlin, M., Lupus hepatitis: an under-recognized disease feature associated with autoantibodies to ribosomal P (1995) Am J Med., 99, pp. 465-472
dc.descriptionKoren, E., Schnitz, W., Reichlin, M., Concomitant development of chronic active hepatitis and antibodies to ribosomal P proteins in a patient with systemic lupus erythematosus (1993) Arthritis Rheum., 9, pp. 1325-1328
dc.descriptionKoscec, M., Koren, E., Wolfson-Reichlin, M., Autoantibodies to ribosomal P proteins penetrate into live hepatocytes and cause cellular dysfunction in culture (1997) J Immunol., 159, pp. 2033-2041
dc.descriptionSontheimer, R.D., Maddison, P.J., Reichlin, M., Serologic and HLA associations in subacute cutaneous lupus erythematosus
dc.descriptiona clinical subset of lupus erythematosus (1982) Ann Intern Med., 97, pp. 664-671
dc.descriptionGrootscholten, C., Van Bruggen, M.C., Van Der Pijl, J.W., Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis (2003) Arthritis Rheum., 48, pp. 1355-1362
dc.descriptionLiang, M.H., Socher, S.A., Larson, M.G., Realiability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus (1989) Arthritis Rheum., 32, pp. 1107-1118
dc.descriptionSymmons, D.P.M., Coopock, J.S., Bacon, P.A., Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus (1988) Q J Med., 68, pp. 927-937
dc.descriptionBombardier, C., Gladman, D.D., Urowits, M.B., Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE (1992) Arthritis Rheum., 35, pp. 630-640
dc.descriptionGuzman, J., Cardiel, M.H., Arce-Salinas, A., Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices (1992) J Rheumatol., 19, pp. 1551-1558
dc.descriptionPetri, M., Buyon, J., Skovron, M.L., Reliability of SELENA-SLEDAI and flares as a clinical trial outcome measure (1998) Arthritis Rheum., 41, pp. S218
dc.descriptionLiang, M.H., Socher, S.A., Roberts, W.N., Measurement of systemic lupus erythematosus activity in clinical research (1988) Arthritis Rheum., 31, pp. 817-825
dc.descriptionPetri, M., Bochemstedt, L., Colman, J., Serial assessment of glomerular filtration rate in lupus nephropathy (1988) Kidney Int., 34, pp. 832-839
dc.descriptionGladman, D., Ginzler, E., Goldsmith, C., The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus (1996) Arthritis Rheum., 39, pp. 363-369
dc.descriptionGladman, D.D., Urowitz, M.B., Rahman, P., Ibanez, D., Tam, L.S., Accrual of organ damage over time in patients with systemic lupus erythematosus (2003) J Rheumatol., 30, pp. 1955-1959
dc.descriptionBeyan, E., Beyan, C., Turan, M., Hematological presentation in systemic lupus erythematosus and its relationship with disease activity (2007) Hematology., 12, pp. 257-261
dc.descriptionHanly, J.G., Neuropsychiatry lupus (2005) Rheum Dis Clin North Am., 31, pp. 273-279
dc.descriptionNishihara, K.K., Furst, D.E., Aspirin and other nonsteroidal anti-inflammatory drugs (1997) Arthritis and allied conditions: a textbook of rheumatology, pp. 611-654. , In: Koopman WJ
dc.descriptioned, Baltimore: Williams & Wilkins
dc.descriptionWallace, D.J., Antimalarials-the 'real' advance in lupus (2001) Lupus., 10, pp. 385-387
dc.descriptionPortnoy, J.Z., Callen, J.P., Ophthalmologic aspects of chloroquine and hydroxychloroquine therapy (1983) Int Dermatol., 22, pp. 273-278
dc.descriptionSapolsky, R.M., Romero, L.M., Munk, A.U., How do glucocorticoids influence stress responses? Integrating permissive
dc.descriptionsuppressive
dc.descriptionstimulatory
dc.descriptionand preparative actions (2000) Endocr Rev., 21, pp. 55-89
dc.descriptionO'Banion M.k, Winn, V.D., Young, D.A., cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase (1992) Proc Natl Acad Sci. USA, 89, pp. 4888-4892
dc.descriptionPaliogianni, F., Ahuja, S.S., Yamada, H., Glucocorticoid inhibit T cell proliferation by downregulating proliferative signals mediated through both T cell antigen and interleukin-2 receptors (1992) Arthritis Rheum., 35, pp. S127
dc.descriptionLynch, J., McCune, W., Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders: state of the art (1997) Am J Respir Crit Care Med., 155, pp. 395-420
dc.descriptionGilchrist, D.M., Friedman, J.M., Teratogenesis and IV cyclophosphamide (letter) (1989) J Rheumatol., 16, pp. 1008-1009
dc.descriptionKirshon, B., Wasserstrum, N., Willis, R., Teratogenic effects of first trimester cyclophophamide therapy (1988) Obstet Gynecol., 72, p. 462
dc.descriptionSztenjnbok, M., Stewart, A., Diamond, H., Azathioprine in the treatment of systemic lupus erythematosus: a controlled study (1971) Arthritis Rheum., 14, pp. 639-645
dc.descriptionMcCune, W.J., Friedman, A.W., Immunosuppressive drug therapy for rheumatic disease (1993) Curr Opin Rheumatol., 5, pp. 282-292
dc.descriptionDeMattos, A., Olvaei, A., Bennett, W., Nephrotoxicity of immunosuppressive: long-term consequences and challenges for the future (2000) Am J Kidney Dis., 35, pp. 333-346
dc.descriptionMello, S., Barros, D., Silva, A., Methotrexate as a preferential cyclooxygenase-2 inhibition in whole blood of patients with rheumatoid arthritis (2000) Rheumatology., 39, pp. 533-536. , (Oxf)
dc.descriptionAllison, A.C., Eugui, E.M., Mycophenolate mofetil and its mechanisms of action (2000) Immunopharmacology., 47, pp. 85-118
dc.descriptionBullingham, R.E., Nicholls, A.J., Kamm, B.R., Clinical pharmacokinetics of mycophenolate mofetil (1998) Clin Pharmacokinet., 34, pp. 429-455
dc.descriptionCarr, S.F., Papp, E., Wu, J.C., Characterization of human type I and type II IMP dehydrogenases (1993) J Biol Chem., 268, pp. 27286-27290
dc.descriptionGoldblum, R., Therapy of rheumatoid arthritis with mycophenolate mofetil (1993) Clin Exp Rheumatol., 11 (SUPPL. 8), pp. S117-S19
dc.descriptionAnderson, K.C., Bates, M.P., Slaughenhoupt, B.L., Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation (1984) Blood., 63, pp. 1424-1433
dc.descriptionMaloney, D.G., Liles, T.M., Czerwinski, D.K., Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma (1994) Blood., 84, pp. 2457-2466
dc.descriptionReff, M.E., Carner, K., Chambers, K.S., Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 (1994) Blood., 83, pp. 435-445
dc.descriptionEdwards, J.C., Szczepanski, L., Szechinski, J., Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis (2004) N Engl J Med., 350, pp. 2572-2581
dc.descriptionCohen, S.B., Emery, P., Greenwald, M.W., Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter
dc.descriptionrandomized
dc.descriptiondouble-blind
dc.descriptionplacebo-controlled
dc.descriptionphase III trial evaluating primary efficacy and safety at twenty-four weeks (2006) Arthritis Rheum., 54, pp. 2793-2806
dc.descriptionEmery, P., Fleischmann, R., Filipowicz-Sosnowska, A., The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized
dc.descriptiondouble-blind
dc.descriptionplacebocontrolled
dc.descriptiondose-ranging trial (2006) Arthritis Rheum., 54, pp. 1390-1400
dc.descriptionHauser, S.L., Waubant, E., Arnold, D.L., B-cell depletion with rituximab in relapsing-remitting multiple sclerosis (2008) N Engl J Med., 358, pp. 676-688
dc.descriptionPescovitz, M., Greenbaum, C., Krause-Steinrauf, H., Rituximab
dc.descriptionB-lymphocyte depletion
dc.descriptionand preservation of beta-cell function (2009) N Engl J Med., 261, pp. 2143-2152
dc.descriptionWallace, D.J., Stohl, W., Furie, R.A., A phase II
dc.descriptionrandomized
dc.descriptiondouble-blind
dc.descriptionplacebo-controlled
dc.descriptiondose-ranging study of belimumab in patients with active systemic lupus erythematosus (2009) Arthritis Rheum., 61, pp. 1168-1178
dc.descriptionPetri, M., Hobbs, K., Gordon, C., Clinically meaningful improvements with epratuzumab (Anti-CD22 mAb targeting b-cells) in patients (Pts) with Moderate/Severe SLE flares: results from 2 randomized controlled trials (2008) Arthritis Rheum., 58, pp. S571
dc.descriptionUrowitz, M.B., Gladman, D.D., Abu-Shakra, M., Farewell, V.T., Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years (1997) J Rheumatol., 24, pp. 1061-1065
dc.descriptionMerrell, M., Shulman, L.E., Determination of prognosis in chronic disease
dc.descriptionillustrated by systemic lupus erythematosus (1955) J Chronic Dis., 1, pp. 12-32
dc.descriptionBjornadal, L., Yin, L., Granath, F., Klareskog, L., Ekbom, A., Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95 (2004) J Rheumatol., 31, pp. 713-719
dc.descriptionWang, L.C., Yang, Y.H., Lu, M.Y., Chiang, B.L., Retrospective analysis of mortality and morbidity of pediatric systemic lupus erythematosus in the past two decades (2003) J Microbiol Immunol Infect., 36, pp. 203-208
dc.descriptionAbu-Shakra, M., Gladman, D.D., Urowitz, M.B., Mortality studies in SLE: how far can we improve survival of patients with SLE (2004) Autoimmun Rev., 3, pp. 418-420
dc.descriptionMoss, K.E., Ioannou, Y., Sultan, S.M., Haq, I., Isenberg, D.A., Outcome of a cohort of 300 patients with systemic lupus erythematosus attending a dedicated clinic for over two decades (2002) Ann Rheum Dis., 61, pp. 409-413
dc.descriptionReveille, J.D., Bartolucci, A., Alarcón, G.S., Prognosis in systemic lupus erythematosus. Negative impact of increasing age at onset
dc.descriptionblack race
dc.descriptionand thrombocytopenia
dc.descriptionas well as causes of death (1990) Arthritis Rheum., 33, pp. 37-48
dc.descriptionWard, M.M., Pyun, E., Studenski, S., Long-term survival in systemic lupus erythematosus. Patient characteristics associated with poorer outcomes (1995) Arthritis Rheum., 38, pp. 274-283
dc.descriptionGinzler, E.M., Diamond, H.S., Weiner, M., Schlesinger, M., Fries, J.F., Wasner, C., A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis (1982) Arthritis Rheum., 25, pp. 601-611
dc.description(2002), 51, pp. 371-374. , Trends in deaths from systemic lupus erythematosus-United States
dc.description1979-1998. MMWR Morb Mortal Wkly RepPistiner, M., Wallace, D.J., Nessim, S., Metzger, A.L., Klinenberg, J.R., Lupus erythematosus in the 1980s: a survey of 570 patients (1991) Semin Arthritis Rheum., 21, pp. 55-64
dc.descriptionNaleway, A.L., Davis, M.E., Greenlee, R.T., Epidemiology of systemic lupus erythematosus in rural Wisconsin (2005) Lupus., 14, pp. 862-866
dc.descriptionNossent, J.C., Systemic lupus erythematosus on the Caribbean island of Curacao: an epidemiological investigation (1992) Ann Rheum Dis., 51, pp. 1197-1201
dc.descriptionVilar, M.J., Sato, E.I., Estimating the incidence of systemic lupus erythematosus in a tropical region (Natal
dc.descriptionBrazil) (2002) Lupus., 11, pp. 528-532
dc.descriptionStahl-Hallengren, C., Jonsen, A., Nived, O., Sturfelt, G., Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age
dc.descriptiondecreasing frequency of renal manifestations and good prognosis (2000) J Rheumatol., 27, pp. 685-691
dc.descriptionJonsson, H., Nived, O., Sturfelt, G., Silman, A., Estimating the incidence of systemic lupus erythematosus in a defined population using multiple sources of retrieval (1990) Br J Rheumatol., 29, pp. 185-188
dc.descriptionVoss, A., Green, A., Junker, P., Systemic lupus erythematosus in Denmark: clinical and epidemiological characterization of a county-based cohort (1998) Scand J Rheumatol., 27, pp. 98-105
dc.descriptionNossent, H.C., Systemic lupus erythematosus in the Arctic region of Norway (2001) J Rheumatol., 28, pp. 539-546
dc.descriptionHopkinson, N.D., Doherty, M., Powell, R.J., Clinical features and race-specific incidence/prevalence rates of systemic lupus erythematosus in a geographically complete cohort of patients (1994) Ann Rheum Dis., 53, pp. 675-680
dc.descriptionNightingale, A.L., Farmer, R.D., De Vries, C.S., Incidence of clinically diagnosed systemic lupus erythematosus 1992-1998 using the UK General Practice Research Database (2006) Pharmacoepidemiol Drug Saf., 15, pp. 656-661
dc.descriptionSomers, E.C., Thomas, S.L., Smeeth, L., Schoonen, W.M., Hall, A.J., Incidence of systemic lupus erythematosus in the United Kingdom
dc.description1990-1999 (2007) Arthritis Rheum., 57, pp. 612-618
dc.descriptionGudmundsson, S., Steinsson, K., Systemic lupus erythematosus in Iceland 1975 through 1984. A nationwide epidemiological study in an unselected population (1990) J Rheumatol., 17, pp. 1162-1167
dc.descriptionLopez, P., Mozo, L., Gutierrez, C., Suarez, A., Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features (2003) Lupus., 12, pp. 860-865
dc.descriptionAlamanos, Y., Voulgari, P.V., Siozos, C., Katsimpri, P., Tsintzos, S., Dimou, G., Epidemiology of systemic lupus erythematosus in northwest Greece. 1982-2001 (2003) J Rheumatol., 30, pp. 731-735
dc.descriptionAnstey, N.M., Bastian, I., Dunckley, H., Currie, B.J., Systemic lupus erythematosus in Australian aborigines: high prevalence
dc.descriptionmorbidity and mortality (1993) Aust NZ J Med., 23, pp. 646-651
dc.descriptionUrowitz, M.B., Bookman, A.A.M., Koehler, B.E., The bimodal pattern of systemic lupus erythematosus (1976) Am J Med., 60, pp. 221-225
dc.descriptionAbu-Shakra, M., Urowitz, M.B., Gladman, D.D., Mortality studies in systemic lupus erythematosus. Results from a single Centre I. Causes of death (1995) J Rheumatol., 22, pp. 1259-1264
dc.descriptionWard, M.M., Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus (1999) Arthritis Rheum., 42, pp. 338-346
dc.languageen
dc.publisherNova Science Publishers, Inc.
dc.relationAutoimmune Disorders: Symptoms, Diagnosis and Treatment
dc.rightsfechado
dc.sourceScopus
dc.titleSystemic Lupus Erythematosus: Definition, Pathogenesis And Treatment
dc.typeCapítulos de libros


Este ítem pertenece a la siguiente institución